11 March 2005
FDA Antiviral Drug Advisory Committee Recommends Unanymously to Approve Entecavir for Hepatitis B Today March 11, the FDA Antiviral Drug Advisory Committee met in Gaithersburg, Maryland to hold a public hearing to consider the approval of entecavir for treatment for hepatitis B chronic infection. The brand name for entecavir is Baraclude.
.................
Under discussion today was the finding of tumors in rodents in pre-clinical studies of entecavir. The FDA cancer advisory group met & discussed this before today, and felt this finding was relevant to humans. This was the subject of much discussion at the hearing. The committee & the FDA felt that we cannot extrapolate the findings in rodents to humans. There may be a risk for humans but we cannot tell based on studies in rodents. They talked about how similar cancerous toxicities were observed preclinically with certain HIV antiretrovirals. The FDA & the committee considered the risk/benefit ratio, weighing the worldwide problem of hepatitis B & the seriousness of this disease, the need for more therapies, and the finding of tumors in rodents. Every committee member and the FDA felt that the benefit of approving entecavir outweighed potential risks. HBV can lead to liver cancer, cirrhosis, and death. All three drugs currently approved for HBV treatment have limitations. Interferon is difficult to tolerate. Adefovir has potential nephrotoxicity. And lamivudine is associated with significant drug resistance. The FDA & the committee found that entecavir should be approved for firstline and secondline HBV therapy. Due to the finding of tumors in rodents taking entecavir and the potential for humans to develop malignancies, Bristol Myers Squibb proposed a post approval safety study that would evaluate the risk for cancers developing in patients 5 to 8 years after starting entecavir, So far in the clinical studies there does not appear to be malignancies associated with entecavir. The FDA and the committee expressed satisfaction with a proposed Safety Study. The details of the study design was the subject of much discussion today, however. 作者: lin12345 时间: 2011-4-6 11:48
没有必要害怕.
FDA and sFDA 没有 1.issue warning, 2. no change in label, 3. has not withdrawn entecavir from market, 4) doctors in Australia continue to use entecavir.
作者: StephenW 时间: 2011-4-6 12:10
interdetect 发表于 2011-4-6 12:01
回复 StephenW 的帖子
“so far不是for ever”!
"有潜在威胁的东西,你就一点也不在意???太拿人命当儿戏了吧???"
ENT 是国家药监局(sFDA)批准和监管? 国家药监局就一点也不在意???作者: interdetect 时间: 2011-4-6 13:02
澳大利亚有TGA (Therapeutic Goods Administration). TGA没有
1. issue any warning about cancer risk for ENT;
2. did not change any ENT label information;
3. did not withdraw ENT from the markets;
4. doctors are prescribing ENT, even today.
啥也不说了,看看恩替卡韦在动物上诱发的肿瘤吧。
Long-term oral carcinogenicity studies of entecavir in mice and rats were carried out . In mouse and rat studies, entecavir was positive for carcinogenic findings.
In mice, lung adenomas were increased in males and females. Lung carcinomas in both male and female mice were increased. Combined lung adenomas and carcinomas were increased in male mice and in female mice. Tumor development was preceded by pneumocyte proliferation in the lung, which was not observed in rats, dogs, or monkeys administered entecavir, supporting the conclusion that lung tumors in mice may be a species-specific event. Hepatocellular carcinomas were increased in males and combined liver adenomas and carcinomas were also increased. Vascular tumors in female mice (hemangiomas of ovaries and uterus and hemangiosarcomas of spleen) were increased. In rats, hepatocellular adenomas were increased in females; combined adenomas and carcinomas were also increased in females. Brain gliomas were induced in both males and females. Skin fibromas were induced in females.
interdetect 发表于 2011-4-6 14:09
啥也不说了,看看恩替卡韦在动物上诱发的肿瘤吧。
Long-term oral carcinogenicity studies of entecavir i ...
Are you a mouse? 作者: StephenW 时间: 2011-4-6 14:26
interdetect 发表于 2011-4-6 14:12
回复 StephenW 的帖子
1. 没人要求恩替撤市,你没必要着急。
Hey, calm down. You are the one who worries about ENT causing cancer. I am the last person to request withdrawal of ENT. I believe in science, not worry. 作者: interdetect 时间: 2011-4-6 14:31